îāļāđāļāļŦāļē
îž
î
āļĨāđāļāļāļāļīāļ
îāļāđāļāļŦāļē
î
Korro Bio Inc
KRROîāđāļāļīāđāļĄāļĨāļāđāļāļĢāļēāļĒāļāļēāļĢāļāļīāļāļāļēāļĄ
12.020USD
+0.040+0.33%
āļāļīāļÂ 10-26 16:00ïžETïž
177.05MāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
āđāļāļĩāđāļĒāļ§āļāļąāļ Korro Bio Inc āļāļĢāļīāļĐāļąāļ
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Inc āđāļāļĢāđāļāļĨāđ
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļKRRO
āļāļ·āđāļāļāļĢāļīāļĐāļąāļKorro Bio Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 03, 2019
āļāļĩāļāļĩāđāļDr. Ram Aiyar, Ph.D.
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ104
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 03
āļāļĩāđāļāļĒāļđāđOne Kendall Square. Building 600-700
āđāļĄāļ·āļāļCAMBRIDGE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02139
āđāļāļĢāļĻāļąāļāļāđ16174681999
āđāļ§āđāļāđāļāļāđhttps://www.korrobio.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļKRRO
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 03, 2019
āļāļĩāļāļĩāđāļDr. Ram Aiyar, Ph.D.
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Korro Bio Inc
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
16.24K
-45.31%
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
33.66K
-17.24%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
24.46K
+30.66%
āļāļģāļāļēāļĄāļāļĩāđāļāļāļāđāļāļĒ
āđāļāļĢāļāļ·āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Korro Bio Inc?
îāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Korro Bio Inc āđāļāđāđāļāđ: Dr. Nessan Bermingham, Ph.D.
āļĄāļĩāļāļĩāđāļŠāļāļēāļāļąāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Korro Bio Inc (KRRO)?
îāļ āļ§āļąāļāļāļĩāđ 2026Q1 āļĄāļĩāļŠāļāļēāļāļąāļāļāļģāļāļ§āļ 215 āđāļŦāđāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Korro Bio Inc āđāļāļĒāļĄāļĩāļĄāļđāļĨāļāđāļēāļĢāļ§āļĄāļāļĢāļ°āļĄāļēāļ 11.84M āļāļīāļāđāļāđāļ 86.30% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ āđāļĄāļ·āđāļāđāļāļĩāļĒāļāļāļąāļāļ§āļąāļāļāļĩāđ 2025Q4 āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļāđāļāđāđāļāļīāđāļĄāļāļķāđāļ 782639.00